Comparison of $^{99m}$Tc-methyl diphosphonate bone scintigraphy and $^{18}$F-fluorodeoxyglucose positron emission tomography/computed tomography to predict histologic response to neoadjuvant chemotherapy in patients with osteosarcoma

Inki Lee, MD, Byung Hyun Byun, MD, PhD, Ilhan Lim, MD, PhD, Byung Il Kim, MD, PhD, Chang-Bae Kong, MD, PhD, Won Seok Song, MD, PhD, Wan Hyeong Cho, MD, PhD, Jae-Soo Koh, MD, PhD, Sang Moo Lim, MD, PhD

Abstract

We compared the usefulness of $^{99m}$Tc-methyl diphosphonate ($^{99m}$Tc-MDP) bone scintigraphy and $^{18}$F-fluorodeoxyglucose (FDG) for positron emission tomography/computed tomography (PET/CT) in predicting histologic response in patients with osteosarcoma receiving neoadjuvant chemotherapy (NAC).

We retrospectively reviewed 62 patients with high-grade osteosarcoma who had received 2 cycles of NAC and surgery. All patients underwent $^{99m}$Tc-MDP bone scintigraphy and $^{18}$F-FDG PET/CT before and after NAC. $^{99m}$Tc-MDP uptake in the primary tumor was measured quantitatively as the maximum tumor-to-nontumor ratio ($T/NT_{max}$) and $^{18}$F-FDG uptake was measured as the maximum standardized uptake value ($SUV_{max}$), before and after NAC. The percent changes of $T/NT_{max}$ (percent changes of the maximum tumor-to-nontumor ratio $[\Delta\%T/NT_{max}]$) and $SUV_{max}$ (percent changes of the maximum standardized uptake value $[\Delta\%SUV_{max}]$) after NAC were calculated and the correlations between these parameters were evaluated. After surgery, the effects of NAC were graded histopathologically (good vs poor) and the optimum cut-off values of $\Delta\%T/NT_{max}$ and $\Delta\%SUV_{max}$ for predicting histologic response were assessed using the receiver operating characteristic (ROC) curve analysis.

$\Delta\%T/NT_{max}$ and $\Delta\%SUV_{max}$ were positively correlated with each other ($r = 0.494, P < .01$). Based on the ROC curve analysis, both $\Delta\%T/NT_{max}$ (area under the curve [AUC] = 0.772, $P < .01$) and $\Delta\%SUV_{max}$ (AUC = 0.829, $P < .01$) predicted good histologic response. However, there was no significant difference between the AUCs of $\Delta\%T/NT_{max}$ and $\Delta\%SUV_{max}$ ($P = .44$). The sensitivity and specificity for predicting good histologic response were 83.3% and 75.0%, for the criterion $\Delta\%T/NT_{max} < -12.5\%$, and 80.0% and 81.3% for the criterion $\Delta\%SUV_{max} < -49.0\%$, respectively.

The $^{99m}$Tc-MDP bone scan and $^{18}$F-FDG PET scan are non-inferior to each other in predicting the histologic response of osteosarcoma treatments. The $^{99m}$Tc-MDP bone scan and $^{18}$F-FDG PET scan showed respective advantages with differing features. Therefore, physicians should consider which scan is appropriate for their own institute based on the advantages of each scan and the circumstances of the institute.

Keywords: $^{18}$F-fluorodeoxyglucose positron emission tomography/computed tomography, $^{99m}$Tc-methyl diphosphonate bone scintigraphy, histologic response, neoadjuvant chemotherapy, osteosarcoma
1. Introduction

Osteosarcoma is not a common malignancy.[1] In the United States, <1% of patients who are newly diagnosed with cancer each year are diagnosed with osteosarcoma.[1] However, it is the most common malignant osseous tumor in children.[1] Before the 1980s, the survival rate of patients with osteosarcoma was about 20% in the United States.[1,2] Even when the primary tumor was controlled, about 80% of patients did not survive due to metastasis. Since then, the survival rate has dramatically improved through the use of chemotherapy.[3] Chemotherapy is therefore currently established as a standard part of osteosarcoma treatment.[4]

For the treatment of osteosarcoma, neoadjuvant chemotherapy (NAC), surgical resection of the primary tumor and adjuvant chemotherapy are included in the current strategy.[5] Furthermore, it has been reported that the histologic response to preoperative chemotherapy is one of the most important prognostic factors for predicting survival.[5,6] However, tumor necrosis, as an indicator of histologic response, is typically checked with the resected specimen after surgery. It is difficult to differentiate the histologic responder and non-responder with NAC prior to surgery. If information about histologic response could be obtained before resection, it would be helpful in making treatment decisions for patients in advance. Therefore, non-invasive imaging methods have been extensively studied for checking histologic response.[7-11] Among them, 99mTc-methyl diphosphonate (99mTc-MDP) bone scan and 18F-fluorodeoxyglucose (FDG) for positron emission tomography/computed tomography (PET/CT) have been used to evaluate the histologic response after treatment. However, to date, there has been no study that directly compared 99mTc-MDP bone scan and 18F-FDG PET for predicting histologic response.

In this study, we compared directly the parameters of 99mTc-MDP bone scan and 18F-FDG PET for predicting histologic response of NAC in the same cohort of the patients with osteosarcoma.

2. Methods

2.1. Patients

A total 62 patients with osteosarcoma were retrospectively reviewed between September 2006 and December 2012. All the patients were treated with NAC and complete resection of the primary tumor. Surgical resection was performed between 6 and 10 weeks after completion of the NAC. 99mTc-MDP bone scan and 18F-FDG PET were performed before and after NAC. The initial scans were obtained within 2 weeks of NAC. The follow up scans after chemotherapy were obtained within 2 weeks prior to surgery. Magnetic resonance imaging (MRI) for evaluating the size of the primary tumor was performed within 2 weeks before NAC.

Our current study analyzed a total of 62 cases, including 21 of 26 cases that had been analyzed in our previous report.[10] along with 41 new cases.

All patients underwent 2 cycles of NAC with high-dose methotrexate, adriamycin, and cisplatin according to the modified T10 protocol.[10,12] The protocol was described in detail in a previous report.[10] Surgical resection of the primary tumor was performed after completion of NAC. A surgical specimen was used for assessing histologic response according to the previous report.[10,13] A tumor with ≥90% necrosis was considered a good response.[13]

The study design was approved by the Review Board of our institution (IRB No.: K-1712-002-031), and written informed consents were exempted by the IRB. All procedures were performed in accordance with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

2.2. Image Acquisition

2.2.1. 99mTc-MDP bone scan. A whole body bone scan (anterior and posterior images) was performed 3 hours after intravenous injection of 740 to 925 MBq of 99mTc-MDP using SymbiaT (Siemens Medical Solutions, Malvern, PA). A low energy, high resolution parallel collimator was used. The photopeak was centered at 140 keV and the matrix size was 256 × 1024.

2.2.2. 18F-FDG PET/CT. The 18F-FDG PET/CT scan was performed as described in the previous report.[10] Patients were intravenously injected with 18F-FDG (8.14 Mbq/kg) after fasting for a minimum of 6 hours and blood glucose level did not exceed 7.2 mmol/L. The PET images were acquired 1 hour after injection using a PET/CT scanner (Biograph6; Siemens Medical Solutions, Malvern, PA). The CT images were obtained for attenuation correction immediately before the acquisition of PET images (130 kVp, 30 mA, 0.6 s/CT rotation, and a pitch of 6). The images were reconstructed with the ordered subsets expectation maximization algorithm (iteration 2, subset 8).

2.2.3. MRI. MR images were obtained with a 3.0-T MRI scanner (MAGNETOM Trio A Tim; Siemens Medical Solutions, Erlangen, Germany). T1-weighted sequence images with or without gadolinium enhancement and T2-weighted sequence without fat suppression images were obtained from all patients. Gadodiamide (Omniscan; GE Healthcare) was injected intravenously. On coronal sections of nonenhanced T1-weighted images, tumor lengths were evaluated, and on axial sections of enhanced T1-weighted sequence without fat suppression, the widths and depths of the tumors were measured.[10]

2.3. Image analysis

For the bone scan, the maximum pixel counts of the primary tumor (anterior image, TAmax; posterior image, TPmax) were obtained by manually drawing the region of interest (ROI), including the lesion with increased uptake compared with adjacent normal bone. To obtain the reference values, the same sized ROI was manually drawn in the contra-lateral area. With this contra-lateral ROI, the maximum pixel counts of the nontumor area (anterior images, NTAmax; posterior images, NTPmax) were acquired. The geometric mean count (GMC) was calculated for tumor or nontumor regions using the following equation:[14]

\[
\text{GMC}_{\text{tumor}} = \sqrt{\frac{T_{\text{Amax}} \times T_{\text{Pmax}}}{\text{GMC}_{\text{nontumor}}}}
\]

The tumor to nontumor ratio (T/NTmax) was calculated as GMC_tumor divided by GMC_nontumor. T/NTmax before the chemotherapy was defined as T/NTmax1. T/NTmax after the chemotherapy was defined as T/NTmax2. The percentage change in T/NTmax (Δ%T/NTmax) between T/NTmax1 and T/NTmax2 was calculated using the following formula: Δ%T/NTmax = (T/NTmax2 − T/NTmax1)/T/NTmax1 × 100.

For the 18F-FDG PET scan, the maximum SUV value (SUVmax) of the primary tumor was acquired by manually drawing the
volume of interest (VOI). The pre-chemotherapy SUV\text{max} was defined as SUV\text{max}_1 and the post-chemotherapy SUV\text{max} was defined as SUV\text{max}_2. The percentage change in SUV\text{max} (Δ\%SUV\text{max}) between SUV\text{max}_1 and SUV\text{max}_2 was calculated using the following formula: Δ\%SUV\text{max} = (SUV\text{max}_2 - SUV\text{max}_1)/SUV\text{max}_1 × 100.

Tumor volume was defined at the initial MRI prior to the NAC as follows: the volume of interest (VOI). The pre-chemotherapy SUV\text{max} was defined as SUV\text{max}_1 and the post-chemotherapy SUV\text{max} was defined as SUV\text{max}_2. The percentage change in SUV\text{max} (Δ\%SUV\text{max}) between SUV\text{max}_1 and SUV\text{max}_2 was calculated using the following formula: Δ\%SUV\text{max} = (SUV\text{max}_2 - SUV\text{max}_1)/SUV\text{max}_1 × 100.

2.4. Statistics

To predict histologic response, the receiver operating characteristic (ROC) curve analyses were performed using the parameters from the 99mTc-MDP bone scan and 18F-FDG PET scan. The areas under the curve (AUCs) for each parameter were calculated and the optimal cut-off values of each parameter for prediction of the histologic response were obtained based on the Youden index. Spearman rank correlation analysis was performed to compare the parameters between the 99mTc-MDP bone scan and 18F-FDG PET scan. To evaluate the influence of the clinical features on the histologic response, logistic regression analyses were performed. P values <.05 were regarded as statistically significant. Statistical analyses were performed using commercial software (Medcalc version 16.4.3, Medcalc software, Ostend, Belgium).

3. Results

3.1. Patient characteristics

Detailed clinical features are described in Table 1. After completion of NAC and surgical resection, good histologic response occurred in 30 patients. The other 32 patients showed poor histologic response.

3.2. ROC curve analysis

In the ROC curve analysis of histologic response using 18F-FDG PET parameters, the AUC for Δ\%SUV\text{max} had the largest value (0.829) compared with other parameters (Fig. 1A). The ROC curve of Δ\%SUV\text{max} was significantly different from that of SUV\text{max}_1 (P < .01), whereas the ROC curve of Δ\%SUV\text{max} was not dissimilar from that of SUV\text{max}_2 (P = .80). In the ROC curve analysis using 99mTc-MDP bone scan, Δ\%T/NT\text{max} showed the largest value of the AUC (0.772) (Fig. 1B). The ROC curve of Δ\%T/NT\text{max} was not significantly different from the curves of T/NT\text{max}_1 and T/NT\text{max}_2 (P = .12 and P = .97, respectively). Based on the ROC curve analysis, Δ\%SUV\text{max} and Δ\%T/NT\text{max} were selected as representative parameters of 18F-FDG PET and 99mTc-MDP bone scan for further analysis.

The optimal cut-off values of Δ\%SUV\text{max} and Δ\%T/NT\text{max} for histologic response after NAC were calculated as −49.0% and −12.5%, respectively. Table 2 shows the sensitivity and specificity for predicting histologic response using the optimal cut-off values of Δ\%SUV\text{max} and Δ\%T/NT\text{max}. Both parameters could predict histologic response with high sensitivity and specificity. In addition, the ROC curves using these parameters did not show a statistically significant difference (P = .44) (Fig. 1C).

3.3. Correlation of parameters between 99mTc-MDP bone scan and 18F-FDG PET

A moderate positive linear correlation between Δ\%SUV\text{max} and Δ\%T/NT\text{max} was observed in the scatter plot (P < .01, rho = .949) (Fig. 2). The mean values of Δ\%SUV\text{max} and Δ\%T/NT\text{max} were −36.8 and 13.4, respectively (P < .01).

3.4. Prognostic values for histologic response

The various clinical features including age, sex, American Joint Committee on Cancer (AJCC) stage, tumor volume based on MRI images, location of the primary tumor, and pathologic type were not statistically significant factors for histologic response based on the univariate logistic regression analyses. However, Δ\%SUV\text{max} and Δ\%T/NT\text{max} were significant prognostic factors for histologic response based on univariate (both P < .01) and multivariate logistic regression analyses (both P < .01) (Table 3).

Representative images of good and poor histologic response are shown in Figs. 3 and 4.

4. Discussion

In this study, we evaluated the histologic response in patients with osteosarcoma after completion of NAC using 99mTc-MDP bone scintigraphy and 18F-FDG PET/CT. The percentage change in SUV\text{max} of the 18F-FDG PET scan and the percentage change in tumor to nontumor ratio in the 99mTc-MDP bone scan significantly predicted the histologic response of preoperative

Table 1

| Characteristics | No. of patients (%) | n=62 |
|-----------------|---------------------|------|
| Age, y          |                     |      |
| <15             | 40 (64.5%)          |      |
| 15 to <40       | 21 (33.9%)          |      |
| >40             | 1 (1.6%)            |      |
| Sex             |                     |      |
| Male            | 46 (74.2%)          |      |
| Female          | 16 (25.8%)          |      |
| AJCC stage      |                     |      |
| IA              | 23 (37.1%)          |      |
| IB              | 35 (56.5%)          |      |
| III             | 2 (3.2%)            |      |
| IV              | 2 (3.2%)            |      |
| Tumor volume, cm³ |                   |      |
| <150            | 44 (71.0%)          |      |
| >150            | 18 (29.0%)          |      |
| Location        |                     |      |
| Distal tibia    | 3 (4.8%)            |      |
| Proximal tibia  | 21 (33.9%)          |      |
| Distal femur    | 28 (45.2%)          |      |
| Proximal femur  | 1 (1.6%)            |      |
| Distal humerus  | 1 (1.6%)            |      |
| Proximal humerus| 2 (3.2%)            |      |
| Proximal fibula | 2 (3.2%)            |      |
| Distal radius   | 3 (4.8%)            |      |
| Proximal radius | 1 (1.6%)            |      |
| Pathologic subtype |                 |      |
| Osteoblastic    | 45 (72.6%)          |      |
| Chondroblastic  | 3 (4.8%)            |      |
| Fibroblastic    | 8 (12.9%)           |      |
| Other           | 6 (9.7%)            |      |
| Histologic response |             |      |
| Good            | 30 (48.4%)          |      |
| Bad             | 32 (51.6%)          |      |
| Total           | 62 (100.0%)         |      |

AJCC = American Joint Committee on Cancer.
Figure 1. ROC curve analysis between the histologic response and each parameter of the $^{18}$F-FDG PET and $^{99m}$Tc-MDP bone scans. In ROC curves using the $^{18}$F-FDG PET parameters (A), $\Delta \%SUV_{\text{max}}$ shows the largest AUC value (0.829). The AUC values for SUV$_{\text{max}1}$ and SUV$_{\text{max}2}$ are 0.571 and 0.817, respectively. In ROC curves using $^{99m}$Tc-MDP bone scan parameters (B), the AUC for $\Delta \%T/NT_{\text{max}}$ has the largest value (0.772). The AUC values for T/NT$_{\text{max}1}$ and T/NT$_{\text{max}2}$ are 0.601 and 0.770, respectively. The ROC curves regarding $\Delta \%SUV_{\text{max}}$ and $\Delta \%T/NT_{\text{max}}$ are compared (C). Two curves did not show significant difference ($P = 0.44$).

$^{18}$F-FDG PET = $^{18}$F-Fluorodeoxyglucose positron emission tomography, $^{99m}$Tc-MDP = $^{99m}$Tc-methyl diphosphonate, $\Delta \%SUV_{\text{max}}$ = percent changes of the maximum standardized uptake value, $\Delta \%T/NT_{\text{max}}$ = percent changes of the maximum tumor-to-nontumor ratio, AUC = area under the curve, ROC = receiver operating characteristic.

Table 2

| Parameter (modality) | Optimal cut-off value | Sensitivity | Specificity | AUC of ROC curve | $P$-value for AUC |
|----------------------|-----------------------|-------------|-------------|------------------|------------------|
| $\Delta \%SUV_{\text{max}}$ (PET) | $\leq -49.0\%$ | 80.0% | 81.3% | 0.829 | $<.01^*$ |
| $\Delta \%T/NT_{\text{max}}$ (bone scan) | $\leq -12.5\%$ | 83.3% | 75.0% | 0.772 | $<.01^*$ |

$\Delta \%SUV_{\text{max}}$ = percent changes of the maximum standardized uptake value, $\Delta \%T/NT_{\text{max}}$ = percent changes of the maximum tumor-to-nontumor ratio, $^{18}$F-FDG = $^{18}$F-fluorodeoxyglucose, $^{99m}$Tc-MDP = $^{99m}$Tc-methyl diphosphonate, AUC = area under the curve, PET = positron emission tomography, ROC = receiver operating characteristic.

$^*$ Statistically significant.

Figure 2. The correlation between $\Delta \%SUV_{\text{max}}$ and $\Delta \%T/NT_{\text{max}}$. A moderate positive correlation exists between the 2 parameters ($P < .01$, rho = .494). $\Delta \%SUV_{\text{max}}$ = percent changes of the maximum standardized uptake value, $\Delta \%T/NT_{\text{max}}$ = percent changes of the maximum tumor-to-nontumor ratio.
chemotherapy in patients with osteosarcoma. To the best of our knowledge, this is the first attempt to directly compare 99mTc-MDP bone scintigraphy and 18F-FDG PET/CT for predicting treatment response.

It was reported that many parameters of 18F-FDG PET/CT are correlated with the histologic response after NAC in the patients with osteosarcoma. For instance, in our previous studies, Δ%SUVmax, metabolic tumor volume (MTV) before NAC, and SUVmax after NAC are associated with histologic response.[10,15] Im et al.[16] reported that SUVmax, peak SUV (SUVpeak), MTV, and total lesion glycolysis (TLG) during and after NAC are correlated with histologic response. It was reconfirmed through the current study that, Δ%SUVmax, the representative parameter, is correlated with the histologic response after NAC.

Bone scan using 99mTc-MDP is a sensitive tool for detecting primary bone tumor and bone metastasis,[19] but it has limitations in reflecting the treatment response in a relatively short time.[17] While 18F-FDG PET directly reflects the metabolism of viable cells, the 99mTc-MDP uptake on bone scan is based on blood flow and ion exchange, meaning that the bone scan reflects indirect osteoblastic activity rather than direct detection of viable tumors.[10] Despite such weakness of the bone scan, it was reported that the changes in tumor-to-background ratio (TBR) on bone scan before and after NAC in patients with osteosarcoma is associated with histologic response.[18] Such is consistent with our results. In the current study, Δ%SUVmax, on the 99mTc-MDP bone scan predicted the histologic response after NAC. Δ%T/NTmax on 99mTc-MDP bone scan and Δ%SUVmax on 18F-FDG PET showed positive correlation with statistical significance. Similarly, Franzius et al.[18] reported that tumor to nontumor ratios on 18F-FDG PET scans before NAC show a significant positive correlation with tumor to nontumor ratios on 99mTc-MDP bone scintigraphy before NAC. When comparing the AUC curves for Δ%SUVmax on the 18F-FDG PET scan and Δ%SUVmax on the 99mTc-MDP bone scan for prediction of histologic response, the AUC values of the 2 parameters were not statistically different. This suggests that both modalities are non-inferior to each other in predicting histologic response. Furthermore, multivariate analyses showed that both parameters are independent prognostic factors for histologic response. Clinical data other than the parameters of 99mTc-MDP bone scan and 18F-FDG PET showed no significant correlation with histologic response. Notably, the tumor volume at initial diagnosis, known as an important independent prognostic factor for metastasis-free survival,[12] did not show any significant correlation with histologic response. This result is consistent with that of a previous report.[19]

However, in our results, the differences between the values before and after treatment were much greater in Δ%SUVmax than in Δ%T/NTmax. Furthermore, although there is no significant difference, the AUC value of Δ%SUVmax was slightly greater than that of Δ%T/NTmax. This suggests that the change from before and after NAC can be more easily detected on the 18F-FDG PET scan than on the 99mTc-MDP bone scan. This may be the result of differences in imaging modalities. The PET/CT image is tomographic while the bone scan is planar. Therefore, PET/CT provides higher resolution images with higher sensitivity and specificity in lesion detection compared with conventional planar bone scans.[20] It is not easy to directly compare PET, a tomographic image, with the bone scan, a planar image. The sensitivity of bone scan for lesion detection is reported to be 70% to 90%.[21] However, SPECT, a tomographic image, can increase the sensitivity for lesion detection to 95%.[21] In this study, SPECT images were not included because it is not a routinely performed test, and this study is a retrospective study. When bone SPECT can be performed to evaluate the treatment response of the primary tumor, lesions can be evaluated with higher sensitivity and higher resolution when compared with the bone scan. Superior resolution of SPECT over the bone scan can provide better ability to differentiate the lesion in the bone versus soft tissue area.

Another weakness of the bone scan compared with PET is the method used to quantify the uptakes. In the current study, semi-quantitative methods were adapted. However, the tools for direct measurement of SUVs have been developed in SPECT, which can solve the quantification problem.[22] It will be essential to compare quantitative results from SPECT and PET for further clarification of this study. Furthermore, it will also be necessary to compare 18F-FDG PET with 18F-Fluoride PET, a novel PET tracer, which exhibits higher sensitivity than bone scans and bone SPECT.

To date, there have been several studies that compared FDG PET/CT and bone scans in osteosarcoma patients, mainly focusing on metastasis. It was reported that 18F-FDG PET/CT not only displays more sensitivity in detecting bone metastasis than the 99mTc-MDP bone scan in the diagnosis of osteosarcoma,[15,23] but also predicts overall and event-free survival of osteosarcoma patients.[18] In addition to the different level of information that may be acquired by PET/CT and a bone scan, another feature of PET/CT is patient convenience. Because the

| Table 3 | Parameters related with histologic response after neoadjuvant chemotherapy in the univariate and multivariate analyses. |
|---------|---------------------------------------------------------------------------------------------------------------|
| Parameter | Cut-off value | Univariate P value | Relative risk | 95% confidence interval | Multivariate P value |
| Age      | 15<, 15–40, 40+ | NS | NS | NS |
| Sex      | NS | NS | NS | NS |
| AJCC stage | NS | NS | NS | NS |
| Tumor volume | 150cm³ | NS | NS | NS |
| Location | NS | NS | NS | NS |
| Pathologic subtype | NS | NS | NS | NS |
| Δ%SUVmax | −49.0% | <0.01* | 32.192 | 2.624–394.992 | <0.01* |
| Δ%T/NTmax | −12.5% | <0.01* | 32.623 | 3.026–351.658 | <0.01* |

Δ%SUVmax=percent changes of the maximum standardized uptake value, Δ%T/NTmax=percent changes of the maximum tumor-to-nontumor ratio, AJCC=American Joint Committee on Cancer, NS=non-significant.

* = significant.
$^{18}$F-FDG PET scan is performed <2 hours after the injection of $^{18}$F-FDG, the total time required is much less than that for a $^{99m}$Tc-MDP bone scan. On the other hand, some advantages of the $^{99m}$Tc-MDP bone scan are its cost-effectiveness$^{[24]}$ and low radiation exposure. The effective dose of a bone scan for an adult is approximately 3 to 4 mSv,$^{[21]}$ whereas the effective dose of a $^{18}$F-FDG PET/CT whole body scan using 10 mCi of $^{18}$F-FDG is about 7 mSv with additional radiation exposure by CT.$^{[24]}$ Bone scans may reduce cost and total radiation exposure when compared with PET/CT.

There are some limitations to our study. First, the scanners for PET and bone scan can affect the uptake count of FDG and MDP. The estimated cut-off values for $\Delta$%$^{18}$F-FDG PET scan and for $\Delta$%T/NTmax on the bone scan may differ. Second, the flare phenomenon may be observed in the bone scan after treatment. It has been mostly observed in patients with breast and prostate cancer.$^{[27]}$ Although there is no report of specific incidence of flare after treatment of osteosarcoma, sufficient time interval after treatment to exclude the flare phenomenon would be needed. In this study, the time interval from the end of the treatment to the bone scan may have been relatively short. Sufficient consideration should be given to the possibility of a flare phenomenon when predicting therapeutic response using bone scans.

**Figure 3.** A 17-year-old male patient underwent neoadjuvant chemotherapy due to osteosarcoma at the right distal femur. The $^{18}$F-FDG PET images before chemotherapy (A) and after chemotherapy (B) are shown as maximum intensity projections. The sagittal fused $^{18}$F-FDG PET images before chemotherapy (C) and after chemotherapy (D) are shown. $\text{SUV}_{\text{max}}$1 of the tumor (white arrow) is 9.4 and $\text{SUV}_{\text{max}}$2 of the tumor after chemotherapy (black arrow) is 3.7. The value of $\Delta$% $\text{SUV}_{\text{max}}$ is -60.9%. The bone scan images before chemotherapy (C) and after chemotherapy (D) are shown. T/NT$\text{max}$1 of initial primary tumor is 15.2 (white arrowhead) and T/NT$\text{max}$2 of tumor after chemotherapy is 4.2 (black arrowhead). $\Delta$%T/NT$\text{max}$ is -72.1%. After surgical resection of the tumor, 96.0% necrosis was observed, which indicated good histologic response with neoadjuvant chemotherapy. $\text{SUV}_{\text{max}}$1 = prechemotherapy maximum standardized uptake value, $\text{SUV}_{\text{max}}$2 = postchemotherapy $\text{SUV}_{\text{max}}$, T/NT$\text{max}$1 = maximum tumor-to-nontumor ratio before the chemotherapy, T/NT$\text{max}$2 = T/NT$\text{max}$ after the chemotherapy, $\Delta$%$\text{SUV}_{\text{max}}$ = percent changes of the $\text{SUV}_{\text{max}}$, $\Delta$%T/NT$\text{max}$ = percent changes of T/NT$\text{max}$.
In conclusion, $^{18}$F-FDG PET/CT and $^{99m}$Tc-MDP bone scintigraphy have been found to be non-inferior to each other in predicting the histologic response of treatments. Both scans had their own advantages although with differing features. Therefore, it is advised that physicians should consider which scan is appropriate for their institute based on the advantages and features of each scan and the circumstance of the institute. If PET/CT is not available, the $^{99m}$Tc-MDP bone scan may be a non-invasive tool for predicting the histologic response to NAC in patients with osteosarcoma.

**Figure 4.** A 34-year-old male patient with osteosarcoma at right proximal tibia who underwent neoadjuvant chemotherapy. The $^{18}$F-FDG PET images before chemotherapy (A) and after chemotherapy (B) are shown as a maximum intensity projection. The axial fused $^{18}$F-FDG PET images before chemotherapy (E) and after chemotherapy (F) are shown. SUV$\text{max}_1$ of the tumor (white arrow) is 4.7 and SUV$\text{max}_2$ of the tumor after chemotherapy (black arrow) is 8.2. The value of $\Delta$% SUV$\text{max}$ is 73.8%. The bone scan images before chemotherapy (C) and after chemotherapy (D) are shown. T/NT$\text{max}_1$ of initial primary tumor is 2.5 (white arrowhead) and T/NT$\text{max}_2$ of tumor after chemotherapy is 27.1 (black arrowhead). $\Delta$% T/NT$\text{max}$ is 983.6%. After surgical resection of the tumor, 5.0% necrosis was observed, which indicated poor histologic response with neoadjuvant chemotherapy. SUV$\text{max}_1$ = prechemotherapy maximum standardized uptake value, SUV$\text{max}_2$ = postchemotherapy maximum standardized uptake value, SUV$\text{max}_1$ = maximum tumor-to-nontumor ratio before chemotherapy, SUV$\text{max}_2$ = maximum tumor-to-nontumor ratio after chemotherapy, $\Delta$% SUV$\text{max}$ = percent changes of the SUV$\text{max}$, $\Delta$% T/NT$\text{max}$ = percent changes of T/NT$\text{max}$.

**Author contributions**

Conceptualization: Inki Lee, Byung Hyun Byun, Byung Il Kim, Chang-Bae Kong, Sang Moo Lim.

Data curation: Chang-Bae Kong, Jae-Soo Koh.

Formal analysis: Inki Lee, Byung Hyun Byun, Ilhan Lim.

Funding acquisition: Chang-Bae Kong, Sang Moo Lim.

Methodology: Won Seok Song, Wan Hyeong Cho, Jae-Soo Koh.

Resources: Won Seok Song, Wan Hyeong Cho.

Supervision: Ilhan Lim, Byung Il Kim, Chang-Bae Kong.

Validation: Inki Lee, Chang-Bae Kong.

Visualization: Inki Lee.
Writing – original draft: Inki Lee, Byung Hyun Byun, Sang Moo Lim.
Writing – review & editing: Inki Lee, Byung Hyun Byun, Chang-Bae Kong, Won Seok Song, Wan Hyeong Cho, Jae-Soo Koh, Sang Moo Lim.

References

[1] Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 2009;115:1531–43.
[2] Taylor WF, Ivens JC, Pritchard DJ, et al. Trends and variability in survival among patients with osteosarcoma: a 7-year update. Mayo Clin Proc 1985;60:91–104.
[3] Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002;20:776–90.
[4] Harris MB, Gieser P, Goorin AM, et al. Treatment of metastatic osteosarcoma at diagnosis: a Pediatric Oncology Group Study. J Clin Oncol 1998;16:3641–8.
[5] Isakoff MS, Bielack SS, Meltzer P, et al. Osteosarcoma: current protocols. J Clin Oncol 2002;20:776–90.
[6] Marina NM, Smeland S, Bielack SS, et al. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncol 2016;17:1396–408.
[7] Taki J, Higuchi T, Sumiya H, et al. Prediction of final tumor response to preoperative chemotherapy by Tc-99m MIBI imaging at the middle of chemotherapy in malignant bone and soft tissue tumors: comparison with Ti-201 imaging. J Orthop Res 2008;26:411–8.
[8] Kobayashi Y, Otaki T, Takeda Y, et al. Evaluation of the effect of preoperative chemotherapy in bone sarcomas. 99mTc-HMDP scintigraphy in 34 cases. Acta Orthop Scand 1998;69:611–6.
[9] Magnan H, Chou AJ, Chou JF, et al. Noninvasive imaging with thallium-201 scintigraphy may not correlate with survival in patients with osteosarcoma. Cancer 2010;116:4147–51.
[10] Kong CB, Byun BH, Lim I, et al. 18F-FDG PET SUVmax as an indicator of histopathologic response after neoadjuvant chemotherapy in extremity osteosarcoma. Eur J Nucl Med Mol Imaging 2013;40:728–36.
[11] Hamada K, Tomita Y, Inoue A, et al. Evaluation of chemotherapy response in osteosarcoma with FDG-PET. Ann Nucl Med 2009;23:89–95.
[12] Rosen G, Marcove RC, Huvos AG, et al. Primary osteogenic sarcoma: eight-year experience with adjuvant chemotherapy. J Cancer Res Clin Oncol 1983;106(suppl):55–67.
[13] Racci G, Bertoni F, Longhi A, et al. Neoadjuvant chemotherapy for high-grade central osteosarcoma of the extremity. Histologic response to preoperative chemotherapy correlates with histologic subtype of the tumor. Cancer 2003;97:3068–75.
[14] Francis H, Ebele Huegette YY, Kwame KA, et al. Quantification of radionuclide uptake levels for primary bone tumors. J Radiat Res Appl Sci 2015;8:182–9.
[15] Byun BH, Kong CB, Lim I, et al. Comparison of 18F-FDG PET/CT and 99mTc-MDP bone scintigraphy for detection of bone metastasis in osteosarcoma. Skelet Radiol 2013;42:1673–81.
[16] Im HJ, Zhang Y, Wu H, et al. Prognostic value of metabolic and volumetric parameters of FDG PET in pediatric osteosarcoma: a hypothesis-generating study. Radiology 2018;287:303–12.
[17] Al-Muqbel KM, Yaghan RJ. Effectiveness of 18F-FDG-PET/CT vs bone scintigraphy in treatment response assessment of bone metastases in breast cancer. Medicine (Baltimore) 2016;95:e3753.
[18] Franzius C, Bielack S, Fliege S, et al. Prognostic significance of 18F-FDG and 99mTc-methylene diphosphonate uptake in primary osteosarcoma. J Nucl Med 2002;43:1012–7.
[19] Bieling P, Rehan N, Winkler P, et al. Tumor size and prognosis in aggressively treated osteosarcoma. J Clin Oncol 1996;14:348–58.
[20] Kuldhrestha RK, Vinjamuri S, England A, et al. The role of 18F-sodium fluoride PET/CT bone scans in the diagnosis of metastatic bone disease from breast and prostate cancer. J Nucl Med Technol 2016;44:217–22.
[21] Montilla-Soler JL, Makanji R. Skeletal scintigraphy. Cancer Control 2017;24:137–46.
[22] Armstrong IS, Hoffmann SA. Activity concentration measurements using a conjugate gradient (Siemens xSPECT) reconstruction algorithm in SPECT/CT. Nucl Med Commun 2016;37:1212–7.
[23] Hurley C, McCarrville MB, Shulkin BL, et al. Comparison of 18F-FDG-PET-CT and bone scintigraphy for evaluation of osseous metastases in newly diagnosed and recurrent osteosarcoma. Pediatr Blood Cancer 2016;63:1381–6.
[24] Wu F, Jiang Y, Ma I, et al. Detection of bone metastases in patients with cancer: 99mTc-MDP bone scan and 18F-FDG PET/CT. Bioromed Res 2017;28:1299–304.
[25] Van den Wyngaert T, Strobel K, Kampen Wu, et al. The EANM practice guidelines for bone scintigraphy. Eur J Nucl Med Mol Imaging 2016;43:1723–38.
[26] Boellaard R, Delgado-Bolton R, Owen WJ, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 2015;42:328–54.
[27] Herrlin K, Willen H, Wiebe T. Flare phenomenon in osteosarcoma after complete remission. J Nucl Med 1995;36:1429–31.